Church & Dwight

source: coverage-next-full ticker: CHD step: "01" title: Business Model & Overview created: 2026-06-03

Step 01 — Business Model & Overview: Church & Dwight Co. (CHD)

1. Executive Summary

Church & Dwight is a $6.2B revenue Consumer Staples company that has compounded at ~5.7% revenue CAGR from 2008 to 2025 through a distinctive M&A-led growth model. Founded in 1846 around ARM & HAMMER baking soda, the company has evolved into a multi-category branded consumer goods platform by systematically acquiring niche-dominant brands in underserved categories, integrating them through its distribution and marketing infrastructure, and growing them above their respective category rates. This "Evergreen Model" has sustained above-peer TSR across multiple decades. [S2]

2. Business Model Canvas

Value Proposition

CHD creates value by:

1. Owning niche category leadership — TROJAN (70% U.S. condom share), WATERPIK (75% water flosser), ARM & HAMMER (#1 laundry by wash loads), THERABREATH (#2 mouthwash)
2. Dual premium/value positioning — Portfolio spans premium (OXICLEAN, THERABREATH, WATERPIK, HERO) and value (XTRA, ARM & HAMMER basic) tiers to capture consumers across economic cycles
3. Acquisition optionality — Consistent M&A pipeline of established consumer brands that management can scale through CHD's distribution, retail relationships, and marketing infrastructure

Revenue Model

Revenue is primarily product sales to mass/grocery/drug/club retailers and increasingly e-commerce (24% of consumer sales in 2025, up from 2% in 2015). Recurring consumption categories provide revenue predictability. [S2]

Cost Structure (FY2025)

Marketing/advertising is the primary lever: CHD spends approximately 11% of sales on advertising, which it adjusts dynamically based on competitive conditions and brand building needs. SBC is well-controlled at 0.9% of sales. [S1][S3]

3. Value Chain Layer Map

Raw Materials (Surfactants, Sodium Bicarbonate, Plastics, Fragrances)
        ↓
Manufacturing (CHD-owned plants + 3PL co-manufacturers)
        ↓
Distribution (Direct to Retailer; limited direct-to-consumer)
        ↓
Retail Shelf (Walmart/Target/Amazon/Grocery/Drug/Club ~48% top retailers)
        ↓
Consumer (Household, Personal Care, Professional/Industrial)

Key observations on the value chain:

• CHD is NOT vertically integrated upstream; raw material inputs are broadly available commodities, limiting COGS advantage but also limiting supply risk
• Manufacturing has been upgraded substantially: $450M in capital improvements since 2022 to support supply chain resilience and tariff mitigation
• Retail concentration is high: top 3 customers represent 48% of Consumer Domestic revenue; Walmart is the largest single customer ($1.4B+ est.)
• E-commerce channel (Amazon, Walmart.com, direct) grew from 2% (2015) to 24% (2025) and is the primary growth driver — bypassing some traditional retail power

4. Segment Deep Dive

Consumer Domestic ($4,775M, 77%)

The core U.S. segment encompasses:

• Household products: ARM & HAMMER laundry detergent, cat litter, baking soda, cleaning products; OXICLEAN stain fighters; XTRA detergent (value)
• Oral care: WATERPIK, THERABREATH (now including toothpaste launch 2026)
• Personal care: TROJAN, FIRST RESPONSE, NAIR, ORAJEL, BATISTE, HERO, TOUCHLAND (acquired 2025)
• FY2025 Consumer Domestic grew 0.8% organically (reset year); Q1 2026 +4.4% organic

Consumer International ($1,129M, 18%)

International operations span 80+ countries with strongest positions in UK (BATISTE), Europe, Australia, and emerging markets. Management has set an explicit target to grow International from 18% to 25%+ of total revenue, viewing it as the underpenetrated volume opportunity for existing power brands. FY2025 organic growth +5.3%. [S2]

Specialty Products Division ($299M, 5%)

Manufactures and sells sodium bicarbonate and specialty chemical products to industrial, agricultural, pharmaceutical, and animal nutrition customers. Steady, low-volatility cash generator with modest growth. Not a strategic priority for reinvestment; serves as a capital contributor to the rest of the portfolio. [S2]

5. The Evergreen Model — Core Strategic Logic

CHD's Evergreen Model [S4][S5] is a documented M&A and growth playbook:

M&A track record:

Capital allocation priority: M&A with TSR-accretive targets > CapEx > New Product Development > Shareholder returns.

6. Competitive Positioning Summary

CHD is not competing head-to-head with P&G across its entire business. The strategy is surgical niche dominance: [S6]

• TROJAN operates in a category P&G doesn't compete in
• WATERPIK holds 75% share in oral irrigators where Colgate and P&G have weak positions
• ARM & HAMMER competes with P&G's Tide on wash loads — and wins on volume despite Tide's marketing budget advantage — by leveraging value pricing and ingredient brand trust
• THERABREATH attacks Colgate's premium mouthwash and toothpaste positions from a clinical/fresh-breath angle

This positioning gives CHD sustainable competitive battles it can win with a smaller budget than the mega-CPG firms.

7. Management & Governance Summary

• CEO: Rick Dierker (assumed role in 2025, previously CFO; open-market purchase of $501K in Aug 2025 signals conviction) [S7]
• Former CEO: Matthew Farrell (retired 2025; presided over 2018–2025 period of strong FCF build-up)
• Board: 11 directors, 10/11 independent, Independent Chair Nils Saligram
• Compensation: ~90% variable; tied to organic sales growth, EPS, and TSR

8. Key Investment Variables

Source Index

Note: Earnings call transcript analysis not performed — coverage-next-full path uses filings and management presentations.

source: coverage-next-full ticker: CHD step: "04" title: Financial Quality & Adversarial Sweep created: 2026-06-03

Step 04 — Financial Quality & Adversarial Sweep: Church & Dwight Co. (CHD)

1. Financial Statement Quality Assessment

Revenue Recognition

CHD recognizes revenue from product sales to retail customers per ASC 606 upon transfer of control. This is straightforward for a consumer goods company: revenue is recognized when product ships or is delivered to retailer. No complex multi-element arrangements or deferred revenue patterns that would distort reported revenue. [S1][S2]

Revenue quality: HIGH. No adjustments needed.

Gross Margin Adjustments

Reported gross margins are clean. The FY2022 compression (41.9%) and recovery (44.7% in FY2025) are genuine commodity-cycle effects, not accounting-driven distortions. No indication of channel stuffing or unsustainable pricing. [S1]

Gross margin quality: HIGH. Reported figures representative of underlying business.

Operating Income Adjustments

The two significant non-recurring items requiring normalization:

Normalized Operating Income Estimates:

FY2025 normalized operating margin (17.4%) is below FY2023 level (18.0%), reflecting the Touchland amortization drag and growth investments. This is a genuine temporary dilution from the $656M acquisition, not a quality concern. [S2][S3]

SBC Analysis

SBC jumped from $32M (FY2022) to $64M (FY2023) — the Hero acquisition-era compensation investment. SBC has stabilized at ~$58–63M (0.9–1.0% of sales), which is below industry median for CPG companies (typically 1.0–1.5%). Not a concern. [S1]

Goodwill & Intangibles

The FY2025 increase in Goodwill (+$195M) and Other Intangibles (+$623M) reflects the Touchland acquisition ($656M net purchase price). The VMS write-down in FY2024 reduced Other Intangibles by ~$357M, bringing them from $3,302M to $2,889M; the subsequent FY2025 Touchland addition rebuilt them to $3,512M. [S1][S2]

Impairment risk assessment: The VMS write-down was specific to a single brand (VITAFUSION/gummies) in a private-label-pressured category. CHD's remaining intangibles are concentrated in HERO (high-growth), THERABREATH (gaining share), WATERPIK (75% share), and TROJAN (70% share) — brands with stronger competitive moats. Near-term impairment risk is low but not zero for BATISTE (losing domestic share). [Judgment]

Working Capital & Cash Conversion

Working capital efficiency improved in FY2025 (inventory down $78M as destocking cleared), contributing to the FCF expansion. DPO of ~78 days is typical for large CPG companies with significant retailer leverage. [S3]

2. Adversarial Research Sweep

Investigation of short reports, SEC investigations, lawsuits, accounting irregularities, and reputational risks.

Active Short Positions / Short Reports

No significant active short thesis identified on CHD as of June 2026. CHD short interest is approximately 1.2–1.5% of float, which is minimal for a large-cap Consumer Staples company. No prominent short seller has published a public attack report on CHD in recent years. [S6]

Historical Litigation & Regulatory Actions

Conclusion: No material active litigation identified. CHD's legal profile is typical for a large consumer goods company: routine product liability claims resolved through insurance, no pattern of material lawsuits or regulatory enforcement. [S2]

Product Safety Concerns

• TROJAN is an FDA-regulated Class II device (condoms as medical devices); no significant recalls or adverse action history
• ZICAM zinc product litigation resulted in product reformulation (prior to CHD's divestiture of ZICAM); CHD retained the reformulated product but has since divested it — removing this risk
• HERO acne patches are cosmetics/OTC; no material safety concerns identified
• WATERPIK is FDA-registered for dental irrigation; no material recalls

Management Integrity Assessment

• CEO transition (Farrell → Dierker 2025) was planned and disclosed proactively; no abrupt resignation signals
• Farrell share sales ($62M over 6 months): Consistent with documented retirement plan (10b5-1); timing pre-dates retirement confirmation; flagged but not an integrity signal
• Dierker open-market purchase ($501K Aug 2025): Positive conviction signal post-appointment
• Financial guidance track record: FY2025 was CHD's first meaningful guidance downgrade in several years (organic growth from 3–4% to 0–2%); management was transparent in disclosing the headwinds. No evidence of sandbagging or inflated guidance patterns. [S4][S7]

Quality of Acquisition Track Record

CHD's acquisitions have predominantly been value-creative with limited write-down history until the VMS (VITAFUSION) impairment:

One meaningful impairment in 15+ acquisitions is a strong track record. VITAFUSION was the exception, not the rule. [S2][Judgment]

Revenue Quality / Channel Check

No evidence of channel stuffing or unsustainable sell-in. FY2025 retail destocking (Consumer Domestic organic ~0.4%) confirmed end-consumer demand was soft, not pump-priming inventory at retail. Q1 2026 organic acceleration (+5%) with volume-driven growth across all three divisions confirms the destocking was a one-time inventory cycle, not demand structural deterioration. [S4]

3. Key Financial Quality Conclusion

Source Index

Note: Earnings call transcript analysis not performed — coverage-next-full path. Commentary on management tone sourced from 8-K press releases and investor presentations.